TMPRSS2-ERG junction oncogene is present in more than 50% of patients with prostate cancer and its expression is frequently associated with poor prognosis. Our aim is to achieve gene knockdown by siRNA TMPRSS2-ERG and then to assess the biological consequences of this inhibition. First, we designed siRNAs against the two TMPRSS2-ERG fusion variants (III and IV), most frequently identified in patients' biopsies. Two of the five siRNAs tested were found to efficiently inhibit mRNA of both TMPRSS2-ERG variants and to decrease ERG protein expression. Microarray analysis further confirmed ERG inhibition by both siRNAs TMPRSS2-ERG and revealed one common down-regulated gene, ADRA2A, involved in cell proliferation and migration. The siRNA against TMPRSS2-ERG fusion variant IV showed the highest anti-proliferative effects: Significantly decreased cell viability, increased cleaved caspase-3 and inhibited a cluster of anti-apoptotic proteins. To propose a concrete therapeutic approach, siRNA TMPRSS2-ERG IV was conjugated to squalene, which can self-organize as nanoparticles in water. The nanoparticles of siRNA TMPRSS2-ERG-squalene injected intravenously in SCID mice reduced growth of VCaP xenografted tumours, inhibited oncoprotein expression and partially restored differentiation (decrease in Ki67). In conclusion, this study offers a new prospect of treatment for prostate cancer based on siRNA-squalene nanoparticles targeting TMPRSS2-ERG junction oncogene.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416711 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0125277 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.
Prostate
January 2020
Department of Pathology and Immunology, Baylor College of Medicine, Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, Texas.
Background: The TMPRSS2/ERG (TE) fusion gene is present in half of the prostate cancers (PCas). The TMPRSS2 and ERG junction of the fusion messenger RNA (mRNA) constitutes a cancer-specific target. Although docetaxel-based chemotherapy is the second line of therapy following development resistance to androgen ablation therapies, it is not curative.
View Article and Find Full Text PDFCharacterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.
Neoplasia
April 2019
Cancer Program, Biomedicine Discovery Institute, Monash University, Victoria, Australia; Department of Biochemistry and Molecular Biology, Monash University, Victoria, Australia. Electronic address:
Approximately 50% of prostate cancers harbor the TMPRSS2:ERG fusion, resulting in elevated expression of the ERG transcription factor. Despite the identification of this subclass of prostate cancers, no personalized therapeutic strategies have achieved clinical implementation. Kinases are attractive therapeutic targets as signaling networks are commonly perturbed in cancers.
View Article and Find Full Text PDFAberrant RNA Splicing in Cancer and Drug Resistance.
Cancers (Basel)
November 2018
Department of Pharmacology and Physiology, School of Medicine and Health Sciences, George Washington University, GW Cancer Center, Washington, DC 20037, USA.
More than 95% of the 20,000 to 25,000 transcribed human genes undergo alternative RNA splicing, which increases the diversity of the proteome. Isoforms derived from the same gene can have distinct and, in some cases, opposing functions. Accumulating evidence suggests that aberrant RNA splicing is a common and driving event in cancer development and progression.
View Article and Find Full Text PDFNew Formulation for the Delivery of Oligonucleotides Using "Clickable" siRNA-Polyisoprenoid-Conjugated Nanoparticles: Application to Cancers Harboring Fusion Oncogenes.
Bioconjug Chem
June 2018
Université Paris-Saclay, Laboratoire de Vectorologie et Thérapeutiques Anticancéreuses, UMR 8203, Villejuif , France - 94805.
Article Synopsis
- The study explores using polyisoprenoid chains, specifically squalene and solanesol, as drug nanocarriers for delivering siRNA targeting the TMPRSS2-ERG oncogene found in prostate cancer.
- A novel copper-free click chemistry method was developed to effectively conjugate these lipids to siRNA, optimizing multiple parameters to achieve high synthesis yields and reproducibility without byproducts.
- The resulting nanoparticles demonstrated reduced oncogene expression in vitro, with some formulations showing promising anti-cancer effects in vivo, indicating potential for broader applications in treating cancer and genetic diseases.
Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.
Cancer Res
July 2018
Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, Maryland.
Article Synopsis
- Oncogenic activation of the ETS-related gene (ERG), mainly through TMPRSS2-ERG gene fusions, is a common mutation in early prostate cancer that the study focuses on.
- Researchers screened small-molecule libraries to find an effective inhibitor of the ERG protein and discovered ERGi-USU, which selectively inhibits the growth of ERG-positive cancer cells while sparing normal cells.
- ERGi-USU shows promising results in combination with enzalutamide and successfully reduced growth in ERG-positive tumor models without toxicity, indicating its potential as a targeted therapy for prostate cancer.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!